A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Trivalent Influenza Vaccine
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 22 Nov 2017 Planned number of patients changed from 240 to 120.
- 22 Nov 2017 Planned End Date changed from 1 Sep 2018 to 30 Jan 2019.
- 22 Nov 2017 Planned primary completion date changed from 1 Jun 2018 to 30 Jan 2019.